Literature DB >> 29385237

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Matthew P Goetz1, Katrin Sangkuhl2, Henk-Jan Guchelaar3, Matthias Schwab4,5,6, Michael Province7, Michelle Whirl-Carrillo2, W Fraser Symmans8, Howard L McLeod9, Mark J Ratain10, Hitoshi Zembutsu11, Andrea Gaedigk12, Ron H van Schaik13,14, James N Ingle1, Kelly E Caudle15, Teri E Klein2.   

Abstract

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.
© 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29385237      PMCID： PMC5931215          DOI： 10.1002/cpt.1007

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  52 in total

1.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

Authors:  Meredith M Regan; Brian Leyland-Jones; Mark Bouzyk; Olivia Pagani; Weining Tang; Roswitha Kammler; Patrizia Dell'orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Patrick Neven; Marc Debled; Rudolf Maibach; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch; James M Rae; Giuseppe Viale
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

2.  Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.

Authors:  Stephanie L Safgren; Vera J Suman; Matthew L Kosel; Judith A Gilbert; Sarah A Buhrow; John L Black; Donald W Northfelt; Anil S Modak; David Rosen; James N Ingle; Matthew M Ames; Joel M Reid; Matthew P Goetz
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

3.  Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Authors:  L Madlensky; L Natarajan; S Tchu; M Pu; J Mortimer; S W Flatt; D M Nikoloff; G Hillman; M R Fontecha; H J Lawrence; B A Parker; A H B Wu; J P Pierce
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

Review 4.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

5.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

Review 6.  PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Authors:  Daniel J Klein; Caroline F Thorn; Zeruesenay Desta; David A Flockhart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-11       Impact factor: 2.089

7.  Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Authors:  Daniel L Hertz; Allison Deal; Joseph G Ibrahim; Christine M Walko; Karen E Weck; Steven Anderson; Gustav Magrinat; Oludamilola Olajide; Susan Moore; Rachel Raab; Daniel R Carrizosa; Steven Corso; Garry Schwartz; Mark Graham; Jeffrey M Peppercorn; David R Jones; Zeruesenay Desta; David A Flockhart; James P Evans; Howard L McLeod; Lisa A Carey; William J Irvin
Journal:  Oncologist       Date:  2016-05-25

8.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

9.  The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.

Authors:  Xianglin Wu; John R Hawse; Malayannan Subramaniam; Matthew P Goetz; James N Ingle; Thomas C Spelsberg
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

10.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Authors:  James M Rae; Suzy Drury; Daniel F Hayes; Vered Stearns; Jacklyn N Thibert; Ben P Haynes; Janine Salter; Ivana Sestak; Jack Cuzick; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506
View more
  84 in total

Review 1.  Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Authors:  Jacob T Brown; Jeffrey R Bishop; Katrin Sangkuhl; Erika L Nurmi; Daniel J Mueller; Jean C Dinh; Andrea Gaedigk; Teri E Klein; Kelly E Caudle; James T McCracken; Jose de Leon; J Steven Leeder
Journal:  Clin Pharmacol Ther       Date:  2019-04-13       Impact factor: 6.875

Review 2.  Essential Characteristics of Pharmacogenomics Study Publications.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; Houda Hachad; Julie A Johnson; Ellen M McDonagh; Mark J Ratain; Mary V Relling; Stuart A Scott; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01       Impact factor: 6.875

3.  Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.

Authors:  Xiaoxia Wei; Hong Sun; Jie Zhuang; Xiuhua Weng; Bin Zheng; Qiwang Lin; Guifeng Zhang; Jiaqin Cai
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

4.  Diversity in the Era of Precision Medicine - From Bench to Bedside Implementation.

Authors:  Abdullah Mamun; Nana Y Nsiah; Meenakshi Srinivasan; Ayyappa Chaturvedula; Riyaz Basha; Deanna Cross; Harlan P Jones; Karabi Nandy; Jamboor K Vishwanatha
Journal:  Ethn Dis       Date:  2019-07-18       Impact factor: 1.847

5.  Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection.

Authors:  Wanqiong Qiao; Suparna Martis; Geetu Mendiratta; Lisong Shi; Mariana R Botton; Yao Yang; Andrea Gaedigk; Raymon Vijzelaar; Lisa Edelmann; Ruth Kornreich; Robert J Desnick; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2018-12-06       Impact factor: 2.533

6.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

7.  CYP2D6 allele frequencies, copy number variants, and tandems in the population of Hong Kong.

Authors:  Wing Chan; Man S Li; Senthil K Sundaram; Brian Tomlinson; Pik Y Cheung; Chi H Tzang
Journal:  J Clin Lab Anal       Date:  2018-08-01       Impact factor: 2.352

8.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 9.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

Review 10.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.

Authors:  Mary V Relling; Teri E Klein; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Kelly E Caudle
Journal:  Clin Pharmacol Ther       Date:  2019-11-05       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.